These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 34181992)

  • 1. Caffeine as a Viscosity Reducer for Highly Concentrated Monoclonal Antibody Solutions.
    Zeng Y; Tran T; Wuthrich P; Naik S; Davagnino J; Greene DG; Mahoney RP; Soane DS
    J Pharm Sci; 2021 Nov; 110(11):3594-3604. PubMed ID: 34181992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studying Excipient Modulated Physical Stability and Viscosity of Monoclonal Antibody Formulations Using Small-Angle Scattering.
    Xu AY; Castellanos MM; Mattison K; Krueger S; Curtis JE
    Mol Pharm; 2019 Oct; 16(10):4319-4338. PubMed ID: 31487466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computational Characterization of Antibody-Excipient Interactions for Rational Excipient Selection Using the Site Identification by Ligand Competitive Saturation-Biologics Approach.
    Jo S; Xu A; Curtis JE; Somani S; MacKerell AD
    Mol Pharm; 2020 Nov; 17(11):4323-4333. PubMed ID: 32965126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of Excipient Effects on Reversible Self-Association, Backbone Flexibility, and Solution Properties of an IgG1 Monoclonal Antibody at High Concentrations: Part 1.
    Hu Y; Arora J; Joshi SB; Esfandiary R; Middaugh CR; Weis DD; Volkin DB
    J Pharm Sci; 2020 Jan; 109(1):340-352. PubMed ID: 31201906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Formulation Development Approach to Identify and Select Stable Ultra-High-Concentration Monoclonal Antibody Formulations With Reduced Viscosities.
    Whitaker N; Xiong J; Pace SE; Kumar V; Middaugh CR; Joshi SB; Volkin DB
    J Pharm Sci; 2017 Nov; 106(11):3230-3241. PubMed ID: 28668340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical Pharmacokinetic Study on Caffeine as an Excipient for Monoclonal Antibody Formulations.
    Zeng Y; Naik S; Tran T; Wuthrich P; Muni N; Mahoney RP
    J Pharm Sci; 2023 Nov; 112(11):2933-2937. PubMed ID: 37517525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel salts of dipicolinic acid as viscosity modifiers for high concentration antibody solutions.
    Ke P; Batalha IL; Dobson A; Tejeda-Montes E; Ekizoglou S; Christie G; McCabe J; van der Walle CF
    Int J Pharm; 2018 Sep; 548(1):682-688. PubMed ID: 30009985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic Effects of Multiple Excipients on Controlling Viscosity of Concentrated Protein Dispersions.
    Yang D; Walker LM
    J Pharm Sci; 2023 May; 112(5):1379-1387. PubMed ID: 36539064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Viscosity-Lowering Effect of Amino Acids and Salts on Highly Concentrated Solutions of Two IgG1 Monoclonal Antibodies.
    Wang S; Zhang N; Hu T; Dai W; Feng X; Zhang X; Qian F
    Mol Pharm; 2015 Dec; 12(12):4478-87. PubMed ID: 26528726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The search for novel proline analogs for viscosity reduction and stabilization of highly concentrated monoclonal antibody solutions.
    Prašnikar M; Proj M; Bjelošević Žiberna M; Lebar B; Knez B; Kržišnik N; Roškar R; Gobec S; Grabnar I; Žula A; Ahlin Grabnar P
    Int J Pharm; 2024 Apr; 655():124055. PubMed ID: 38554741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Near Infrared Spectroscopy as a PAT tool for monitoring and control of protein and excipient concentration in ultrafiltration of highly concentrated antibody formulations.
    Thakur G; Hebbi V; Rathore AS
    Int J Pharm; 2021 May; 600():120456. PubMed ID: 33711473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Osmolality and Hemolysis of High-Concentration Monoclonal Antibody Formulations.
    Pang MJ; Wang MW; Mao LF; Guo Z; Qian C; Zheng XH; Fang WJ
    Pharm Res; 2024 Feb; 41(2):281-291. PubMed ID: 38172366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intermolecular Interactions and the Viscosity of Highly Concentrated Monoclonal Antibody Solutions.
    Binabaji E; Ma J; Zydney AL
    Pharm Res; 2015 Sep; 32(9):3102-9. PubMed ID: 25832501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Product-Specific Impact of Viscosity Modulating Formulation Excipients During Ultra-High Concentration Biotherapeutics Drug Product Development.
    Rodrigues D; Tanenbaum LM; Thirumangalathu R; Somani S; Zhang K; Kumar V; Amin K; Thakkar SV
    J Pharm Sci; 2021 Mar; 110(3):1077-1082. PubMed ID: 33340533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Manufacturing of High-Concentration Monoclonal Antibody Formulations via Spray Drying-the Road to Manufacturing Scale.
    Gikanga B; Turok R; Hui A; Bowen M; Stauch OB; Maa YF
    PDA J Pharm Sci Technol; 2015; 69(1):59-73. PubMed ID: 25691715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterizing monoclonal antibody formulations in arginine glutamate solutions using
    Kheddo P; Cliff MJ; Uddin S; van der Walle CF; Golovanov AP
    MAbs; 2016 Oct; 8(7):1245-1258. PubMed ID: 27589351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of histidine on the stability and physical properties of a fully human antibody in aqueous and solid forms.
    Chen B; Bautista R; Yu K; Zapata GA; Mulkerrin MG; Chamow SM
    Pharm Res; 2003 Dec; 20(12):1952-60. PubMed ID: 14725359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Making Concentrated Antibody Formulations Accessible for Vibrating-Mesh Nebulization.
    Beck-Broichsitter M
    J Pharm Sci; 2019 Aug; 108(8):2588-2592. PubMed ID: 30885662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Technology development to evaluate the effectiveness of viscosity reducing excipients.
    Banik N; Braun S; Gerit Brandenburg J; Fricker G; Kalonia DS; Rosenkranz T
    Int J Pharm; 2022 Oct; 626():122204. PubMed ID: 36116691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spray-Dried Monoclonal Antibody Suspension for High-Concentration and Low-Viscosity Subcutaneous Injection.
    Huang C; Chen L; Franzen L; Anderski J; Qian F
    Mol Pharm; 2022 May; 19(5):1505-1514. PubMed ID: 35417176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.